Latest filings (excl ownership)
15-12G
Securities registration termination
30 Sep 22
EFFECT
Notice of effectiveness
22 Sep 22
EFFECT
Notice of effectiveness
22 Sep 22
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Sep 22
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Sep 22
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Sep 22
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Sep 22
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Sep 22
POS AM
Prospectus update (post-effective amendment)
16 Sep 22
POS AM
Prospectus update (post-effective amendment)
16 Sep 22
8-K
Completion of Acquisition or Disposition of Assets
16 Sep 22
25-NSE
Exchange delisting
16 Sep 22
425
Business combination disclosure
15 Sep 22
8-K
Syros and Tyme Technologies Announce Stockholder Approval of Merger
15 Sep 22
425
Business combination disclosure
7 Sep 22
8-K
TYME Technologies. Inc. Announces Proxy Advisory Firms Glass Lewis and ISS Recommend Stockholders Vote “FOR” Proposed Merger of Syros and Tyme
7 Sep 22
8-K
Departure of Directors or Certain Officers
6 Sep 22
425
Business combination disclosure
2 Sep 22
8-K
Other Events
2 Sep 22
DEFA14A
Additional proxy soliciting materials
29 Aug 22
8-K
Other Events
24 Aug 22
10-Q
2023 Q1
Quarterly report
9 Aug 22
DEFM14A
Proxy related to merger
8 Aug 22
10-K/A
2022 FY
Annual report (amended)
15 Jul 22
425
Business combination disclosure
6 Jul 22
425
Business combination disclosure
5 Jul 22
425
Business combination disclosure
5 Jul 22
8-K
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
5 Jul 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Jun 22
10-K
2022 FY
Annual report
25 May 22
8-K
Departure of Directors or Certain Officers
28 Apr 22
8-K
Entry into a Material Definitive Agreement
19 Apr 22
8-K
TYME Technologies, Inc. Announces Exploration of Strategic Options
29 Mar 22
8-K
Departure of Directors or Certain Officers
25 Mar 22
8-K
TYME Technologies, Inc. Provides Business Update and Announces Third Fiscal
11 Feb 22
10-Q
2022 Q3
Quarterly report
11 Feb 22
8-K
TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer
26 Jan 22
8-K
Regulation FD Disclosure
18 Jan 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Dec 21
8-K
TYME Technologies, Inc. Announces Additional Encouraging Preclinical Data on
14 Dec 21
Latest ownership filings
4
Gerald H Sokol
16 Sep 22
4
Steve Hoffman
16 Sep 22
4
FRANK L. PORFIDO
16 Sep 22
4
Douglas A Michels
16 Sep 22
4
TIMOTHY TYSON
16 Sep 22
4
Barbara Galaini
16 Sep 22
4
Jonathan Eckard
16 Sep 22
4
James Biehl
16 Sep 22
4
Richard Anthony Cunningham,
16 Sep 22
4
Christine D. Baker
16 Sep 22
4
David Carberry
16 Sep 22
4
Donald W DeGolyer
16 Sep 22
SC 13G/A
Hoffman Steve
16 Sep 22
SC 13D/A
Syros Pharmaceuticals, Inc.
16 Sep 22
4
Michael Demurjian
7 Sep 22
4
Donald W DeGolyer
29 Aug 22
4
David Carberry
29 Aug 22
4
Christine D. Baker
29 Aug 22
4
Douglas A Michels
29 Aug 22
4
Gerald H Sokol
29 Aug 22
4
TIMOTHY TYSON
29 Aug 22
4
Steve Hoffman
26 Aug 22
4
Michael Demurjian
23 Aug 22
4
Michael Demurjian
26 Jul 22
SC 13D
Syros Pharmaceuticals, Inc.
13 Jul 22
SC 13D
Syros Pharmaceuticals, Inc.
13 Jul 22
4
Michael Demurjian
12 Jul 22
4
Michael Demurjian
28 Jun 22
4
Michael Demurjian
27 Jun 22
4
Steve Hoffman
23 Jun 22
4
Michael Demurjian
15 Jun 22
4
Steve Hoffman
10 Jun 22
4
Michael Demurjian
2 Jun 22
4
Steve Hoffman
27 May 22
4
Michael Demurjian
17 May 22
4
Michael Demurjian
17 May 22
4
Steve Hoffman
11 May 22
4
Michael Demurjian
3 May 22
4
Steve Hoffman
29 Apr 22
4
Barbara Galaini
26 Apr 22